Taurin in combined treatment of metabolic syndrome and diabetes mellitus

Abstract


In addition to information on the prevalence, etiology and pathogenesis of metabolic syndrome and type 2 diabetes mellitus, the role of insulin resistance, lipotoxicity, hyperglycemia and glucose toxicity in development complications of metabolic syndrome and diabetes mellitus, the article presents evidence from multicenter clinical trials of taurin/dibicor efficacy in the treatment of metabolic syndrome, diabetes mellitus, cardiovascular complications, diabetic retinopathy. It is demonstrated that taurin/ dibicor has a positive effect on insulin resistance and body mass in obesity, on carbohydrate and lipid metabolism, on cell membranes, blood pressure, acuity of vision. Taurin/dibicor protects against macro- and microvascular diabetic complications, improves vision, cardiovascular system condition, quality and duration of life.

About the authors

Aleksandr Sergeevich Ametov

Irina Ivanovna Kochergina

Email: kii7@yandex.ru

Elena Valer'evna Doskina

Birlant Said-Mukhamedovna Abaeva

Evgeniya Pavlovna Elizarova

A S Ametov

Russian Academy of Advanced Medical Training

Russian Academy of Advanced Medical Training

I I Kochergina

Russian Academy of Advanced Medical Training

Russian Academy of Advanced Medical Training

E V Doskina

Russian Academy of Advanced Medical Training

Russian Academy of Advanced Medical Training

B S-M Abaeva

Russian Academy of Advanced Medical Training

Russian Academy of Advanced Medical Training

E P Elizarova

Russian Academy of Advanced Medical Training

Russian Academy of Advanced Medical Training

References

  1. Reaven G. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
  2. Ferranini E., Natali A. et al. Insulin resistance, hyperinsulinemia and blood pressure: role of age and obesity. European Group for the study of insulin resistance (EGIR). Hypertension 1997; 30: 1144-1149.
  3. UKPDS Group. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observation study. Br. Med. J. 2000; 321: 405-413.
  4. Ackermann D., Hemsen H. A. Hypoglycemic effect of taurine. J. Physiol Chem. 1935; 235: 115-121.
  5. Michalk D. V., Wingenfeld P., Licht C. H. Protection against cell damage due to hypoxia and reoxygenation: the role of taurine and the involved mechanisms. Amino Acids 1997; 13: 337-346.
  6. Wu Q. D., Wang J. H., Fennessy F. et al. Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis. Am. J. Physiol. 1999; 277; 1229-1238.
  7. Докшина Г. А., Силаева Т. Ю., Ярцев Е. И. Некоторые инсулиноподобные эффекты таурина. Вопр. мед. химии 1976; 22(1): 503-507.
  8. Kulakowski Е. С., Maturo J. Hypoglycemic properties of taurine: not mediated by enhanced insulin release. Biochem Pharmacol. 1984; 33(18): 2835-2838.
  9. Maturo J., Kulakowski E. C. Taurine binding to the purified insulin receptor. Biochem. Pharmacol. 1988; 37(19): 3755- 3760.
  10. Lee S. H. Enhancing effect of taurine on glucose response in UCP2-overexpressing beta cell. Diabet. Res. Clin. Pract. 2004; 66(suppl. 1): 69-74.
  11. Di Leo M. A., Santini S. A., Silveri N. G. et al. Lone-term taurine supplementation reduces mortality rate in streptozotocin-induced diabetic rats. Amino Acids 2004; 27(2): 187-191.
  12. Seghieri G., Tesi F., Bianchi L. et al. Taurine in women with a history of gestational diabetes. Diabet. Res. Clin. Pract. 2006; 3(1): 15-20.
  13. Zhang M., Bi L. F., Su X. L. et al. Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects. Gpncircg Toyama, Japan, 2002: 56(2): 97-99.
  14. Chang L., Xu J., Yu F. et al. Taurine protected myocardial mitochondria injury induced by hyperhomocysteinemia in rats. Amino Acids 2004; 27: 37-48.
  15. Wharton B. A., Morley C. N., Isaacs E. B. et al. Low plasma taurine and later neurodevelopment. Arch. Dis. Childh. Fetal. Neonatal. Ed. 2004; 89(5): 76-81.
  16. Sadzuka Y., Matsuura M., Sonobe T. The effect of taurine, a novel biochemical modulator, on the antitumor activity of Doxorubicin. Biol. Pharm. Bull. 2009; 32(9): 1584-1587.
  17. Nandhini A. T., Thirunavukkarasu V., Anuradha C. V. Stimulation of glucose utilization and inhibition of protein glycation and AGE products by taurine. Acta Physiol. Scand. 2004; 181(3): 297-303.
  18. Li C., Cao L., Zeng Q. et al. Taurine may prevent diabetic rats from developing cardiomyopathy also by downregulating angiotensin II type 2 receptor expression. Cardiovasc. Drugs Ther. 2005; 19(2): 105-112.
  19. Weiss S. J. et al. Chlorination of taurine by human neutrophils. J. Clin. Invest 1982; 70: 598-607.
  20. Кахновский И. М., Королева Е. В., Захарченко В. Н., Ларионов С. М. Таурин в лечении сахарного диабета. Клин. фармакол. и тер. 1997; 3: 10-12.
  21. Han J., Bae J. H. et al. Taurine increases glucose sensitivity of UCP2-overexpressing beta-cells by ameliorating mitochondrial metabolism. Am. J. Physiol. Endocrinol. Metab. 2004; 287(5): E1008-E1018.
  22. Li C., Xu J., Yu F. et al. Taurine protected myocardial mitochondria injury induced by hyperhomocysteinemia in rats. Amino Acids 2004; 27: 37-48.
  23. Nandhini A. T., Thirunavukkarasu V., Anuradha C. V. Stimulation of glucose utilization and inhibition of protein glycation and AGE products by taurine. Acta Physiol. Scand. 2004; 181(3): 297-303.
  24. Yamory L. et al. Taurine and cardiac study. Clin. Exp. Pharmacol. Physiol. 2004; 20(1): 15-21.
  25. Аметов А. С., Кочергина И. И. Применение дибикора при сахарном диабете и сердечно-сосудистой патологии. М.: ПИК ФАРМА; 2009.
  26. Влияние дибикора на обмен веществ при сахарном диабете типа 1 и 2. М.: ПИК-ФАРМА; 2006.
  27. Недосугова Л. В., Елизарова Е. П., Балаболкин М. И. Метаболическая терапия сахарного диабета дибикором: новые данные. Лечащий врач 2004; 5: 20-21.
  28. Глузкер А. А. Таурин в комплексном лечении больных недостаточностью кровообращения IIА стадии: Дис. ... канд. мед. наук. М.; 1998.
  29. Заволовская Л. И., Елизарова Е. П., Орлов В. А. Клиническая эффективность тауфона в комбинированном лечении больных с хронической недостаточностью кровообращения. Экспер. и клин. фармакол. 1995; 58(2): 29-32.
  30. Мановицкая А. В. Эффекты дибикора у больных с метаболическим синдромом. Качество жизни. Медицина 2008; 3: 41-46.
  31. Anthrayose C. V., Shashidhar S. Studies on protein and taurine in normal, senile and diabetic cataractous human lenses. Indian J. Physiol. Pharmacol. 2004; 48(3): 357-360.
  32. Malone J. I., Lowitt S., Cook W. R. Non-osmotic diabetic cataracts. Pediatr. Res. 1990; 27: 293-296.

Statistics

Views

Abstract - 125

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2011 Ametov A.S., Kochergina I.I., Doskina E.V., Abaeva B.S., Elizarova E.P., Ametov A.S., Kochergina I.I., Doskina E.V., Abaeva B.S., Elizarova E.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies